

Last Thursday, an unidentified government official was reported in some local newspapers as saying that a CNY20 billion (USD2.9 billion) bilateral aid agreement with China has been concluded, which will include a deposit and a Yuan currency swap. While he did not elaborate further on the magnitude of the Yuan currency swap, we take this opportunity to explain the benefits and risks related to utilising the Yuan-denominated currency swap.

How does the currency swap work?

At inception of the currency swap, the People’s Bank of China (PBOC) will provide the Central Bank of Egypt (CBE) with a certain amount of Yuan in return for an EGP equivalent amount, using the CNY/USD and EGP/USD exchange rates. Then, the CBE will be able to offer the local Egyptian banks with Yuan in order to settle import transactions from China. During the term of the swap, both counterparties exchange fixed or floating interest payments on the principal amounts. At swap maturity, the CBE will repay the initial Yuan-denominated amount, and receive the initial EGP lump sum.

Limitations to a Yuan swap

In that context, we note there are two main limitations on the use of the aforementioned Yuan swap: (1) It cannot be used to repay USD-denominated debt, and (2) It cannot be used to import goods or services from another country except for China.

Mutual benefits


For China, providing trading partners with Yuan currency swaps has been another move on the road to expand, albeit gradually, the use of the Renminbi on the international arena. For Egypt, it marks an opportunity to support the CBE’s FCY reserves whilst slightly ease local demand for the USD. We note that China is a major trade partner with Egypt representing c.7% of Egypt’s total foreign trade in FY2015/16. Egyptian imports from China recorded USD5.2 billion in FY2015/16 (c.8% of total imports in FY2015/16).

Minimal risk of Yuan devaluation versus the Dollar

We note that the CBE reports its net international reserves (NIR) in USD. Hence, holding part of the NIR in Yuan can impact the value of NIR in case of Yuan devaluation versus the USD. However, this should not be much of a concern, as the Yuan-denominated portion of NIR is small. The same risk applies on the CNY/USD exchange rate difference at the time of swap maturity versus that at the time of swap inception.

To sum it up, we believe that acquiring a Yuan currency swap provides the CBE with an extra tool to stabilise the current high USD demand, in addition to more FX liquidity at a reasonable cost.

Figure 1 | Currency Swap Mechanism



Source: Pharos Research



Sales and Trading

Mohamed Radwan
Head of Equities
+202 27393680
mohamed.radwan@pharosholding.com

Ahmed Raafat
Local Institutional Sales
+202 27393687
ahmed.raafat@pharosholding.com

Sherif Shebl
Regional Sales
+202 27393679
sherif.shebl@pharosholding.com

Ahmed Abutaleb
Foreign Sales
+202 27393684
ahmed.abutaleb@pharosholding.com

Seif Attia
High Net Worth
+202 27393682
seif.attia@pharosholding.com

Disclaimer

This Report is compiled and furnished solely for informative purposes to be considered by the intended recipients who have the knowledge to assess the information contained herein. Pharos Research ("Pharos") makes no representation or warranty, whether expressed or implied, as to the accuracy and/or completeness of the information contained herein or any other information that may be based on the data/information enclosed. Furthermore, Pharos hereby disclaims any and all liabilities of any nature relating to or resulting from the use of the contents of this Report. This Report shall not be approached as an investment solicitation nor shall it be considered as legal or tax advice. Pharos highly recommends that those viewing this Report seek the advice of professional consultants. None of the materials provided in this Report may be used, reproduced or transmitted, in any form or by any means, electronic or mechanical, including recording or the use of any information storage and retrieval system, without written permission from Pharos.

This report was prepared, approved, published and distributed by Pharos Securities Brokerage company located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by LXM LLP USA, a U.S. registered broker dealer, on behalf of Pharos Securities Brokerage only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through LXM LLP USA.

Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.

Analyst Certification. Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. Please bear in mind that (i) Pharos Securities Brokerage is the employer of the research analyst(s) responsible for the content of this report and (ii) research analysts preparing this report are resident outside the United States and are not associated persons of any US regulated broker-dealer and that therefore the analyst(s) is/are not subject to supervision by a US broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Important US Regulatory Disclosures on Subject Companies. This material was produced by Analysis Pharos Securities Brokerage solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by LXM LLP USA and elsewhere in the world by Pharos Securities Brokerage or an authorized affiliate of Pharos Securities Brokerage. This document does not constitute an offer of, or an invitation by or on behalf of Pharos Securities Brokerage or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which Pharos Securities Brokerage or its Affiliates consider to be reliable. None of Pharos Securities Brokerage accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

LXM LLP USA assumes responsibility for the research reports content in regards to research distributed in the U.S. LXM LLP USA or its affiliates has not managed or co-managed a public offering of securities for the subject company in the past 12 months, has not received compensation for investment banking services from the subject company in the past 12 months, does not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next 3 months. LXM LLP USA has never owned any class of equity securities of the subject company. There are not any other actual, material conflicts of interest of LXM LLP USA at the time of the publication of this research report. As of the publication of this report LXM LLP USA, does not make a market in the subject securities.